FIFE-based retinal imaging company epipole is set to grow its presence within the global ophthalmic imaging market after raising £1.3m in new investment.
The company’s handheld epiCam enables clinicians to record epiStreams – scans of the retina using real-time video – from which high-quality images can be extracted for further examination.
epipole has also appointed experienced med-tech executive Conal Harte as CEO from Össur, a leading global orthopaedics company, where he served as Managing Director Emerging Markets. Harte replaces Founder Craig Robertson, who moves to the position of Chief Technology Officer where he will develop further applications for epipole’s patented technology.
Following the latest round of investment, further recruitment has also been initiated in the US to support the company’s product launch there and early commercialization within primary care optometry and general ophthalmology practices.
epipole Chairman Ian Stevens said: “I am pleased to welcome Conal to the company. He joins at a crucial moment in our development and brings significant commercial experience of growing disruptive medical technologies in international markets.”
Conal Harte said: “I am delighted to have the opportunity to join the epipole team at such an exciting time. Our unique approach to retinal imaging will help our clinician customers deliver an outstanding level of eye care to their patients through a market-leading technology that delivers exceptional imaging in a powerful, portable and low-cost device. This latest investment round will kickstart our US growth ambitions.”
The investment fundraise was led by Greenwood Way Capital and supported by Scottish Enterprise. epipole was advised by Catherine Feechan, a partner at law firm Davidson Chalmers Stewart.